Heart Failure: Evolving Treatment Choices and New Guidance

The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2022. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF there are currently no approved therapies although there are agents in phase 3 clinical trials.

Share

Program Content

Activities

  • Heart Failure
    Heart Failure: Evolving Treatment Choices and New Guidance
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2022

    Expires: October 23, 2023

Provided by

ProCE Banner
ProCE Banner

Jointly provided by PCME and Rockpointe.

Supporters

This program is supported by an educational grant from Merck & Co, Inc.

Merck & Co., Inc.